Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Recruiting 5Unknown 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Glioma 8Multiple Myeloma 7Sarcoma 6Rhabdoid Tumor 6Medulloblastoma 6Wilms Tumor 5Rhabdomyosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Ependymoma 5Central Nervous System Neoplasms 5Breast Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Osteosarcoma 4Pancreatic Neoplasms 3Lung Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Sarcoma, Ewing 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Malignant Solid Neoplasm 2

Interventions

Carboplatin 85pembrolizumab 78Pemetrexed 68Cisplatin 56Paclitaxel 45osimertinib 41Nivolumab 40durvalumab 37Docetaxel 33atezolizumab 20Gemcitabine 18Radiotherapy 17Radiosurgery 16amivantamab 15Ipilimumab 15130-nm albumin-bound paclitaxel 14Taxes 13Specimen Handling 12Magnetic Resonance Spectroscopy 12Crizotinib 11lazertinib 9Radiation 9Immunoglobulin G 9Drug Therapy 9Disulfides 9Bevacizumab 9tislelizumab 8cemiplimab 8alectinib 8Erlotinib Hydrochloride 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Non-Small-Cell Lung × X-Rays × Clear all
NCT03831932 2026-05-28

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
22 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡